We are live on ! Find out more
CBMG

Cellular Biomedicine Group, Inc.
CBMG

Delisted

CBMG was delisted on the 19th of February, 2021.

Back to rankings

22 hedge funds and large institutions have $11.2M invested in Cellular Biomedicine Group, Inc. in 2015 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,600% more capital invested

Capital invested by funds: $416K → $11.2M (+$10.8M)

1,600% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 1

267% more funds holding

Funds holding: 6 → 22 (+16)

Holders
22
Holders Change
+16
Holders Change %
+266.67%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
4
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JMPWA
JP Morgan Private Wealth Advisors
California
+$2.54M
2
DCM
Driehaus Capital Management
Illinois
+$1.31M
3
EI
EAM Investors
California
+$823K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$575K
5
CS
Credit Suisse
Switzerland
+$452K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
JMPWA
1
JP Morgan Private Wealth Advisors
California
$2.96M +$2.54M +94,172 New
DCM
2
Driehaus Capital Management
Illinois
$1.53M +$1.31M +48,522 New
EI
3
EAM Investors
California
$958K +$823K +30,450 New
Geode Capital Management
4
Geode Capital Management
Massachusetts
$850K +$270K +10,009 +59%
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
$669K +$575K +21,270 New
UBS Group
6
UBS Group
Switzerland
$525K +$379K +14,037 +527%
CS
7
Credit Suisse
Switzerland
$525K +$452K +16,716 New
PAM
8
Panagora Asset Management
Massachusetts
$474K +$407K +15,078 New
WC
9
Wexford Capital
Florida
$431K +$370K +13,700 New
Northern Trust
10
Northern Trust
Illinois
$296K +$255K +9,419 New
Millennium Management
11
Millennium Management
New York
$283K +$243K +8,984 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$271K +$233K +8,611 New
VKH
13
Virtu KCG Holdings
New York
$267K +$229K +8,487 New
Renaissance Technologies
14
Renaissance Technologies
New York
$258K +$222K +8,200 New
BIT
15
BlackRock Institutional Trust
California
$211K +$160K +5,903 +738%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$209K +$179K +6,628 New
Morgan Stanley
17
Morgan Stanley
New York
$199K +$170K +6,296 +19,079%
Zurich Cantonal Bank
18
Zurich Cantonal Bank
Switzerland
$186K +$159K +5,900 New
Deutsche Bank
19
Deutsche Bank
Germany
$110K +$94.6K +3,500 New
TRCT
20
Tower Research Capital (TRC)
New York
$15K +$12.5K +463 New
MFS
21
MSI Financial Services
Massachusetts
$3K – – –
Wells Fargo
22
Wells Fargo
California
$1K +$1.16K +43 New
Goldman Sachs
23
Goldman Sachs
New York
– -$152K -11,798 Closed

CBMG Hedge Fund Activity: Q1 2015 in Review

22 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2015, worth a combined $11.2M — up 2,600% from $416K a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CBMG positions and 1 closed out — a net gain of 16 holders — while 4 added to existing stakes and 0 trimmed.

The largest buyer was JP Morgan Private Wealth Advisors, opening a new position worth an estimated $2.54M. The largest seller was Goldman Sachs, exiting entirely with an estimated $152K sold.

  • 22 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2015, up from 6 in Q4 2014.
  • Funds reported $11.2M of Cellular Biomedicine Group, Inc. stock for Q1 2015, up 2,600% quarter-over-quarter.
  • 17 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2015 and 1 closed out, a net change of +16 holders.
  • The largest Cellular Biomedicine Group, Inc. buyer in Q1 2015 was JP Morgan Private Wealth Advisors, an estimated $2.54M added.
  • The largest Cellular Biomedicine Group, Inc. seller in Q1 2015 was Goldman Sachs, an estimated $152K sold.

Based on aggregated 13F filings for Q1 2015.